Abstract 997P
Background
Microvascular invasion (MVI) is an independent poor factor for early recurrence (ER) and long-term outcomes in hepatocellular carcinoma (HCC) after hepatectomy. A practical, convenient, and accurate risk classifications is urgently needed to predict ER risk in HCC patients with MVI and to guide those patients to choose suitable adjuvant therapies to reduce postoperative recurrence risks and prolong long-term survival.
Methods
Data of 440 HCC patients with MVI after curative hepatectomy were retrospectively reviewed. They were randomly divided into a training set and a validation set. Kaplan-Meier curves and Cox regression analyses were used to identify independent prognostic factors of ER. Classification and regression tree (CART) analysis was used to develop ER risk classification in the training set and verified in the validation set.
Results
Multivariate analysis revealed that seven factors, namely, hepatitis B virus deoxyribonucleic acid load, tumor size, Edmondson-Steiner grade, MVI classification, satellite nodules, Ki67 positive index, and cytokeratin 19 expression were independent risk indexs for ER in HCC patients with MVI. The CART strategy showed a good concordance statistics of 0.77 in predicting ER risk, and had a better net benefit and a wider threshold probability range, as well as had a good agreement between the predicted value and actual observed value. The area under the time-dependent receiver operating characteristic curve of the CART strategy in predicting 1-, 3-, and 5-years recurrence-free survival (RFS) were 0.75, 0.78, and 0.84, respectively, and the corresponding overall survival (OS) were 0.74, 0.74, and 0.72, respectively, which were all significantly higher than other eight commonly classic HCC system stages (BCLC stage, Okuda stage, TNM stage, CNLC stage, French stage, CLIP score and JIS score). The ER, RFS and OS were greatly discrepancies between patients that had been stratified into three risk groups. Similar results were obtained in the validation set.
Conclusions
The CART strategy achieved optimal prediction for ER, RFS and OS for HCC patients with with MVI after curative hepatectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This research was supported by the National Natural Science Foundation of China (NO. 82060427, 82103297), Guangxi Key Research and Development Plan (NO. GUIKEAB19245002), Guangxi Scholarship Fund of Guangxi Education Department, Guangxi Natural Science Foundation (NO. 2020GXNSFAA259080).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18